HOOKIPA and Gilead Announced Amended Collaboration to Develop Immunotherapies Against HIV
Feb 16, 2022 By MarketDepth
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced it has entered into an amended and restated collaboration and license agreement with Gilead Sciences, Inc. (NASDAQ: GILD) to advance the development of a novel arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV).
Platform for Immunotherapies
In April 2018, Gilead licensed exclusive rights to HOOKIPA’s versatile arenaviral platform to develop immunotherapies for HIV and hepatitis B virus (HBV). Under those terms, the companies agreed to collaborate through a joint research phase, after which time Gilead had rights for further development. Under the amended and restated agreement, HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial, with funding from Gilead via an upfront payment and equity purchases. At the completion of the Phase 1b trial, Gilead has the exclusive right to assume further development of the program. The HBV portion of the agreement remains unchanged.
“We are pleased to enter into this amended agreement with Gilead which includes provisions that we believe benefit both parties, and we hope ultimately the HIV community. Gilead is helping to advance our novel arenaviral platform technology, which has the potential to complement Gilead’s overall research strategies for cures of HIV and HBV.”
Joern Aldag, Chief Executive Officer at HOOKIPA
